Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
Pieris Pharmaceuticals的合并伙伴Palvella Therapeutics获得了美国食品药品监督管理局孤儿产品开发办公室多至260万美元的拨款，用于QTORIN 3.9％苹果酸雷帕霉素无水凝胶用于微囊性淋巴管畸形的第3期SELVA试验。
Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
pieris pharmaceuticals的并购合作伙伴Palvella Therapeutics获得了FDA孤儿产品开发办公室高达260万美元的补助金，用于QTORIN 3.9% 雷帕霉素无水凝胶用于微囊性淋巴管畸形的3期SELVA试验。
资讯热榜
更新时间